Predictive molecular classifiers in colorectal cancer

Pierre Bohanes, Melissa J LaBonte, Thomas Winder, Heinz-Josef Lenz, Melissa LaBonte Wilson

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)


The introduction of predictive molecular markers has radically enhanced the identification of which patients may benefit from a given treatment. Despite recent controversies, KRAS mutation is currently the most recognized molecular predictive marker in colorectal cancer (CRC), predicting efficacy of anti-epidermal growth factor receptor (anti-EGFR) antibodies. However, other relevant markers have been reported and claimed to identify patients that will benefit from anti-EGFR therapies. This group of markers includes BRAF mutations, PI3KCA mutations, and loss of PTEN expression. Similarly, molecular markers for cytotoxic agents' efficacy also may predict outcome in patients with CRC. This review aims to summarize the most important predictive molecular classifiers in patients with CRC and further discuss any inconsistent or conflicting findings for these molecular classifiers.

Original languageEnglish
Pages (from-to)576-87
Number of pages12
JournalSeminars in Oncology
Issue number4
Publication statusPublished - Aug 2011

Bibliographical note

Copyright © 2011 Elsevier Inc. All rights reserved.


  • Animals
  • Biomarkers, Pharmacological
  • Carcinoma
  • Colorectal Neoplasms
  • Genes, erbB-1
  • Humans
  • Models, Biological
  • Molecular Targeted Therapy
  • Prognosis
  • Tumor Markers, Biological


Dive into the research topics of 'Predictive molecular classifiers in colorectal cancer'. Together they form a unique fingerprint.

Cite this